TP53 and colorectal carcinoma: However, no clear survival benefit for wild-type (wt) p53 was observed in our previous study of 5-FU treated CRC patients (Van Triest et al, 2000), and the presence of p53 mutations failed to predict which patients would benefit from 5-FU-based adjuvant chemotherapy in large retrospective clinical trials (Allegra et al, 2003; Russo et al, 2005).